GlassScriptPhysician profile
Mary Milam
NPI 1063415735
$22,717.47
in general payments reported to CMS, 2019-2025
85 companies · $3,403 in 2025
The $3,403 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,092 · 2020: $2,031 · 2021: $2,942 · 2022: $3,278 · 2023: $4,245 · 2024: $3,726 · 2025: $3,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,982.34 |
| Education | $392.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,825.37 | 2019-2025 | |
| Pfizer INC. | $1,354.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,243.60 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $1,091.88 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Incyte Corporation | $1,029.90 | 2019-2025 | Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $990.97 | 2021-2024 | Injectafer |
| Lilly USA, LLC | $939.47 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $834.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $774.89 | 2019-2025 | Cabometyx |
| Celgene Corporation | $724.42 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $608.80 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $576.70 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Seagen INC. | $570.67 | 2019-2023 | Adcetris |
| Taiho Oncology, INC. | $563.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $546.55 | 2019-2025 | Calquence, Enhertu, Imfinzi |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Milam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.